0000000001095898

AUTHOR

Caputo V.

showing 2 related works from this author

Cross-sectional survey of canine leishmaniasis in Pantelleria island in Sicily

2019

Dogs are the major reservoir of Leishmania infantum, the causative agent of canine visceral and cutaneous human leishmaniasis in the Mediterranean basin. Canine and human leishmaniosis are endemic in Italy, particularly in central and southern regions, including islands. Here we show a preliminary, clinical, serological and molecular study carried out in Pantelleria island during 2017. In this study, we clinically examined 136 dogs for the presence of symptoms compatible with leishmaniasis, determined the titer of anti-Leishmania antibodies, and investigated Leishmania DNA by real time PCR in blood and/or lymph node of each dog. The prevalence of disease was equal to 27% with 95% CI [21%; 3…

IslandsMalelcsh:Veterinary medicinePantelleria islandReal-Time Polymerase Chain ReactionCross-Sectional StudiesDogsCanine leishmaniasis Leishmania infantum Pantelleria islandPrevalenceAnimalsLeishmaniasis Viscerallcsh:SF600-1100FemaleDog Diseaseslcsh:Animal cultureLeishmania infantumSicilyCanine Leishmaniasislcsh:SF1-1100Veterinaria Italiana
researchProduct

NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri eve…

2021

OBJECTIVE: The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects. Chemotherapy-induced nausea and vomiting (CINV) are amongst the most troublesome side effects that impair patients’ adherence to treatments and their quality of life (QoL). NEPA (Akynzeo®), is an oral fixed-dose combination of netupitant [a neurokinin-1 receptor antagonist (NK1RA), 300 mg] and palonosetron [(5-hydroxytryptamine (serotonin or 5HT) type3 receptor antagonist (5HT3RA), 0.5 mg] which has been shown to be effective in preventing CINV. PATIENTS AND METHODS: This prospective study started before…

MalePyridinesVomitingCINVLeucovorinCOVID-19NauseaMiddle AgedIrinotecanColorectal cancerBevacizumabOxaliplatinPalonosetronNetupitantAntineoplastic Combined Chemotherapy ProtocolsAntiemeticsHumansEmetogenic chemotherapyFemaleFluorouracilProspective StudiesColorectal NeoplasmsPandemicsAdvanced pancreatic cancerAgedEuropean review for medical and pharmacological sciences
researchProduct